# Session Handoff — AR Platform Audit & Improvement

**Session Date:** 2026-04-12
**Platform Version:** v9.0
**Scope:** 4-Part systematic platform audit per user specification

---

## Completed This Session

### Part 1: Five-Stock Compliance Audit
- Audited all 5 STOCKS entries against the 6-stage equity research skill
- Web-verified all data against April 2026 market reality
- Found ALL 5 stocks severely stale (12+ months)
- Identified 3 thesis integrity alerts (BeiGene fully realized, BYD massively exceeded, Innolight confirmed)
- VP arithmetic inconsistencies found in 300308.SZ (7pt gap) and 6160.HK (4.3pt gap)
- Platform-wide compliance: 2.1/5

### Part 2: Option Ranking
- Ranked: A (VP Rewrite) > C (AKShare Spec) > B (Sector Screening) > D (Short Framework)
- Rationale: BeiGene's fully invalidated VP was a data integrity emergency; architectural improvements (C) are highest-leverage long-term but don't solve immediate false-precision

### Part 3: BeiGene VP Reconstruction (EXECUTED)
- Rebuilt 6160.HK from scratch in Dashboard.jsx
- New thesis: ZS combo (sonrotoclax+Brukinsa) as second growth curve vs market's single-drug deceleration narrative
- VP: 71 -> 65 (arithmetic-verified: 65.2 from decomposition)
- Updated: name (BeOne), price (HK$1,440), all financials ($3.9B rev), 4 new catalysts, 4 risks, pipeline focus
- All catalyst dates are forward-looking (H2 2026 onward)

### Part 4: This Handoff Document

---

## Files Modified

| File | Change |
|------|--------|
| `src/Dashboard.jsx` | BeiGene STOCKS entry completely rebuilt (lines ~150-173) |
| `AUDIT_PART1.md` | NEW — Full audit report |
| `AUDIT_PART2.md` | NEW — Option ranking with rationale |
| `AUDIT_PART3.md` | NEW — BeiGene reconstruction details |
| `SESSION_HANDOFF.md` | NEW — This file |

---

## Immediate Next Actions (Priority Order)

### 1. Rebuild BYD VP (002594.SZ) — URGENT
Same situation as BeiGene: the rightIf trigger (350K exports) was exceeded by 2.6x (900K+). VP=52 is severely understated. Needs fresh variant view around whatever the market is wrong about *now* (likely: margin sustainability in non-China markets, or technology licensing revenue from VW/Toyota).

### 2. Refresh Innolight Data (300308.SZ) — HIGH
Thesis was confirmed (GM 42.6% vs our 42% estimate). All catalyst dates expired. Revenue was 38.2B vs platform's 16.8B. VP arithmetic gap of 7 points needs fixing. Less urgent than BYD because the directional thesis is still valid (SiPh ramp), just needs updated numbers and new catalysts.

### 3. Refresh Tencent (700.HK) and NetEase (9999.HK) — MEDIUM
Both have stale financials and expired catalyst dates. Tencent's AI monetization thesis is partially realized (QClaw launched). NetEase's Marvel Rivals data needs updating (40M+ players, $136M first month). Neither has a fully invalidated thesis — they need refreshes, not rebuilds.

### 4. AKShare Integration Spec (Option C) — STRATEGIC
The root cause of all staleness. Without automated data feeds, every VP score degrades daily. This should be a dedicated session focused on:
- AKShare API endpoints for A-share and HK equities
- Data mapping to STOCKS object fields
- Refresh scheduling (daily? weekly?)
- Staleness indicators in the UI

### 5. VP Auto-Calculation — TECHNICAL DEBT
Currently VP is a manually-entered number separate from the decomposition sub-scores. The formula (30/25/20/15/10 weights) should be computed automatically from decomp values. This eliminates the arithmetic drift found in the audit (3 of 5 stocks had discrepancies).

### 6. Catalyst Lifecycle Management — ARCHITECTURE
No mechanism to mark catalysts as resolved/expired/replaced. All 5 stocks had past-dated catalysts. Need: status field (PENDING/RESOLVED/EXPIRED), auto-flagging when date < today, and ability to mark resolution outcome (CONFIRMED/DENIED/MIXED).

---

## Known Issues Not Addressed

- **Vercel deployment still pending user action:** API key setup, Vercel project creation, env var configuration, code push. The Deep Research feature (Claude API) only works on Vercel, not GitHub Pages.
- **Other 4 stocks remain stale:** Only BeiGene was rebuilt. The remaining 4 need at minimum a data refresh.
- **VP formula is fixed 30/25/20/15/10:** No sector adjustment (Option B). AI Infra stocks should weight catalyst_prox higher; Biotech should weight fundamental_acc differently.
- **No short framework:** Platform has zero short positions or short-specific fields (borrow cost, short interest, squeeze risk).
- **No technical analysis layer:** Price/volume data not integrated.
- **No "last updated" timestamp:** Users cannot tell when data was last refreshed.

---

## Architecture State

```
ar-platform/
├── api/research.js         ← Vercel serverless (Claude API) — NOT YET DEPLOYED
├── src/Dashboard.jsx       ← Main component (~1030 lines) — UPDATED this session
├── vercel.json             ← Vercel config — ready
├── vite.config.js          ← Dual deployment base path — ready
├── package.json            ← v2.0 with @anthropic-ai/sdk — ready
├── DEPLOY.md               ← Deployment guide — ready
├── AUDIT_PART1.md          ← NEW this session
├── AUDIT_PART2.md          ← NEW this session
├── AUDIT_PART3.md          ← NEW this session
└── SESSION_HANDOFF.md      ← NEW this session
```

---

*Session complete. All 4 parts delivered.*
